Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
With the complete acquisition of Life Edit, ElevateBio will be able to integrate that company’s genome editing capabilities with its cell and gene therapies.
Bristol Myers Squibb is reportedly courting Canada’s Aurinia Pharmaceuticals to strike a buyout deal.
Numerous biopharma and life sciences companies have sought to put their stocks up for sale, but this week, two companies opted to pull out their IPO due to concerns over market stability.
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Calithera Biosciences is expanding its oncology portfolio with the addition of two clinical-stage compounds from Takeda Pharmaceuticals.
Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.
Cue Health went public on September 24 on the Nasdaq securities exchange under the ticker symbol HLTH.